Refine by
Mitochondrial Dysfunctional Suppliers & Manufacturers
6 companies found
based inNorth Lanarkshire, UNITED KINGDOM
Strathkelvin Instruments was founded in 1981, to develop instruments based upon precision dissolved oxygen measurement, for use in the biomedical research field. This remains a significant part of the company's instrumentation range. In 1998, the ...
based inGangnam-gu, SOUTH KOREA
MitoImmune Therapeutics Inc. is a drug discovery and development biotech company that harnesses the power of mitochondria and its proprietary technology targeting mitochondria as the source for developing new potential breakthrough therapeutics. Our ...
based in, MASSACHUSETTS (USA)
MtoZ Biolabs is an integrate contract research organization (CRO) providing advanced proteomics, metabolomics, bioinformatics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. The ...
based inheongju-si, SOUTH KOREA
Curome Biosciences is an innovative R&D company developing therapies to treat mitochondrial dysfunction-related diseases with high unmet medical needs. Curome Biosciences wants to provide solutions for treatment of diseases with high unmet medical ...
Mitochondria are an essential cellular organelle that is responsible for the generation of energy (known as the ‘powerhouse of the cell’). Mitochondrial dysfunction is related with numerous diseases. ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
Tigilanol tiglate (EBC-46) is a protein kinase C (PKC)/C1 domain activator. Tigilanol tiglate is associated with mitochondrial/endoplasmic reticulum (ER) dysfunction, leading to activation of the unfolded protein ...
based inSan Francisco, CALIFORNIA (USA)
ViCardia Therapeutics, Inc., a Delaware corporation, founded in 2017, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for treating heart failure (HF) involving ...
ViCardia is entering Phase 2 with GP531, a potent, long-lasting, infusion therapy that treats mitochondrial dysfunction that leads to chronic heart failure and ultimately to acute decompensated heart failure. ...